Entropy Technologies LP purchased a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 3,500 shares of the company's stock, valued at approximately $548,000.
A number of other institutional investors have also recently made changes to their positions in the company. State Street Corp lifted its position in shares of Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company's stock valued at $264,455,000 after buying an additional 119,936 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Krystal Biotech by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company's stock valued at $107,714,000 after purchasing an additional 11,411 shares during the period. Franklin Resources Inc. raised its stake in shares of Krystal Biotech by 34.2% during the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock valued at $43,774,000 after purchasing an additional 62,178 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Krystal Biotech by 9.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company's stock valued at $43,727,000 after purchasing an additional 19,777 shares during the period. Finally, Braidwell LP raised its stake in shares of Krystal Biotech by 57.4% during the 3rd quarter. Braidwell LP now owns 168,691 shares of the company's stock valued at $30,707,000 after purchasing an additional 61,512 shares during the period. Hedge funds and other institutional investors own 86.29% of the company's stock.
Krystal Biotech Price Performance
NASDAQ KRYS traded down $2.51 during trading on Friday, reaching $153.24. The company's stock had a trading volume of 129,478 shares, compared to its average volume of 236,087. The stock has a market capitalization of $4.41 billion, a PE ratio of 86.58 and a beta of 0.84. The firm has a fifty day moving average of $158.61 and a 200 day moving average of $175.74. Krystal Biotech, Inc. has a one year low of $107.50 and a one year high of $219.34.
Analysts Set New Price Targets
A number of research firms recently issued reports on KRYS. HC Wainwright reiterated a "buy" rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. Chardan Capital reiterated a "buy" rating and set a $212.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. Finally, Citigroup boosted their price objective on Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $206.67.
Check Out Our Latest Stock Report on Krystal Biotech
Insiders Place Their Bets
In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 14.10% of the company's stock.
About Krystal Biotech
(
Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
